MYHEALTHCHECKED PLC |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.75 GBX | +3.30% |
|
+23.68% | -11.32% |
| Jan. 11 | MyHealthChecked expects 2023 earnings breakeven | AN |
| Jan. 11 | MyHealthChecked PLC Provides Revenue Guidance for the Full Year 2023 | CI |
| Sales 2021 | 16.38M 20.91M | Sales 2022 | 22.31M 28.5M | Capitalization | 12.29M 15.69M |
|---|---|---|---|---|---|
| Net income 2021 | 2M 2.55M | Net income 2022 | 1M 1.28M | EV / Sales 2021 | 0.69 x |
| Net cash position 2021 | 6.39M 8.16M | Net cash position 2022 | 7.56M 9.65M | EV / Sales 2022 | 0.21 x |
| P/E ratio 2021 |
8.7
x | P/E ratio 2022 |
8.29
x | Employees | 21 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 55.04% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.30% | ||
| 1 week | +23.68% | ||
| Current month | +17.50% | ||
| 1 month | +20.51% | ||
| 3 months | -7.84% | ||
| 6 months | +17.50% | ||
| Current year | -11.32% |
1 week
9.75
12.00
1 month
8.8212.00
Current year
8.8216.00
1 year
8.2625.00
3 years
8.2670.50
5 years
8.26111.72
10 years
8.26340.05
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 19-11-13 | |
Bhavika Patel
CTO | Chief Tech/Sci/R&D Officer | 37 | - |
| Director/Board Member | 66 | 22-04-10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Adam Reynolds
CHM | Chairman | 59 | 16-02-16 |
Lyn Rees
BRD | Director/Board Member | 51 | 19-11-13 |
| Director/Board Member | 58 | 17-03-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 11.75 | +3.30% | 23 595 |
| 24-05-24 | 11.38 | -3.60% | 26,337 |
| 24-05-23 | 11.8 | +4.89% | 289,324 |
| 24-05-22 | 11.25 | +18.42% | 457,217 |
| 24-05-21 | 9.5 | +5.56% | 80,761 |
Delayed Quote London S.E., May 28, 2024 at 03:40 am EDT
More quotes
MyHealthChecked PLC is a United Kingdom-based consumer home-testing healthcare company. The Company is the umbrella brand of a range of at-home rapid tests, as well as deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and blood sample collection kits. The Company also provides COVID tests. The Company's multi-platform portfolio of tests offers users access to a variety of test types, sample collection options, and levels of analysis, enabling it to meet diverse customer needs. The tests are lateral-flow self-tests, whilst the sample collection kits enable the collection of blood, urine, nasal or mouth swab samples that are analyzed in partner laboratories for a range of biomarkers. The tests have been made available online and for over-the-counter purchase. All its business activity is underpinned by two distinct routes to market: business to business to consumer (B2B2C) and direct to consumer.
Calendar
2024-06-03
- Q4 2023 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -11.32% | 7.56M | |
| +10.03% | 223B | |
| +13.59% | 195B | |
| +20.01% | 144B | |
| +30.83% | 111B | |
| +2.02% | 65.19B | |
| +15.38% | 53.02B | |
| +3.64% | 50.28B | |
| +8.37% | 44.15B | |
| +3.27% | 36.45B |
- Stock Market
- Equities
- FRI Stock